TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
MARKET SHARE 13
FIVE FORCES ANALYSIS 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Substitutes 20
Rivalry 21
LEADING COMPANIES 22
Bayer AG 22
GlaxoSmithKline Plc 28
Johnson & Johnson 33
MARKET DISTRIBUTION 38
MARKET FORECASTS 39
Market value forecast 39
MACROECONOMIC INDICATORS 40
APPENDIX 42
Methodology 42
Industry associations 43
Related Datamonitor research 43
Disclaimer 45
ABOUT DATAMONITOR 46
Premium Reports 46
Summary Reports 46
Datamonitor consulting 46
LIST OF TABLES
Table 1: Italy OTC pharmaceuticals market value: $ million, 2005–09 10
Table 2: Italy OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Table 3: Italy OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Table 4: Italy OTC pharmaceuticals market share: % share, by value, 2009 13
Table 5: Bayer AG: key facts 22
Table 6: Bayer AG: key financials ($) 25
Table 7: Bayer AG: key financials (€) 25
Table 8: Bayer AG: key financial ratios 26
Table 9: GlaxoSmithKline Plc: key facts 28
Table 10: GlaxoSmithKline Plc: key financials ($) 30
Table 11: GlaxoSmithKline Plc: key financials (£) 31
Table 12: GlaxoSmithKline Plc: key financial ratios 31
Table 13: Johnson & Johnson: key facts 33
Table 14: Johnson & Johnson: key financials ($) 35
Table 15: Johnson & Johnson: key financial ratios 36
Table 16: Italy OTC pharmaceuticals market distribution: % share, by value, 2009 38
Table 17: Italy OTC pharmaceuticals market value forecast: $ million, 2009–14 39
Table 18: Italy size of population (million), 2005–09 40
Table 19: Italy gdp (constant 2000 prices, $ billion), 2005–09 40
Table 20: Italy gdp (current prices, $ billion), 2005–09 40
Table 21: Italy inflation, 2005–09 41
Table 22: Italy consumer price index (absolute), 2005–09 41
Table 23: Italy exchange rate, 2005–09 41
LIST OF FIGURES
Figure 1: Italy OTC pharmaceuticals market value: $ million, 2005–09 10
Figure 2: Italy OTC pharmaceuticals market segmentation I:% share, by value, 2009 11
Figure 3: Italy OTC pharmaceuticals market segmentation II: % share, by value, 2009 12
Figure 4: Italy OTC pharmaceuticals market share: % share, by value, 2009 13
Figure 5: Forces driving competition in the OTC pharmaceuticals market in Italy, 2009 14
Figure 6: Drivers of buyer power in the OTC pharmaceuticals market in Italy, 2009 16
Figure 7: Drivers of supplier power in the OTC pharmaceuticals market in Italy, 2009 17
Figure 8: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Italy, 2009 18
Figure 9: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Italy, 2009 20
Figure 10: Drivers of degree of rivalry in the OTC pharmaceuticals market in Italy, 2009 21
Figure 11: Bayer AG: revenues & profitability 26
Figure 12: Bayer AG: assets & liabilities 27
Figure 13: GlaxoSmithKline Plc: revenues & profitability 32
Figure 14: GlaxoSmithKline Plc: assets & liabilities 32
Figure 15: Johnson & Johnson: revenues & profitability 36
Figure 16: Johnson & Johnson: assets & liabilities 37
Figure 17: Italy OTC pharmaceuticals market distribution: % share, by value, 2009 38
Figure 18: Italy OTC pharmaceuticals market value forecast: $ million, 2009–14 39
[Cerrar la tabla de contenidos]
